ENOB Stock - Enochian Biosciences, Inc.
Unlock GoAI Insights for ENOB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-188,966,000 | $-81,639,000 | $-38,556,891,000,000 | $-116,079,000 | $-23,402,000 |
| Net Income | $-178,007,489 | $-80,650,000 | $-39,684,056,000,000 | $-113,433,000 | $-26,724,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.08 | $-0.84 | $-705301.71 | $-2.16 | $-0.57 |
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
Visit WebsiteEarnings History & Surprises
ENOBEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | — | $0.13 | — | — |
Q3 2025 | Sep 29, 2025 | — | $-0.77 | — | — |
Q2 2025 | May 15, 2025 | — | $0.00 | — | — |
Q1 2025 | Feb 19, 2025 | — | $-0.54 | — | — |
Q1 2025 | Feb 19, 2025 | — | $-0.04 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-0.28 | — | — |
Q4 2024 | Oct 10, 2024 | — | $459366.26 | — | — |
Q1 2024 | Feb 14, 2024 | — | $-68777.27 | — | — |
Q4 2023 | Oct 2, 2023 | — | $-698425.13 | — | — |
Q2 2023 | May 12, 2023 | — | $-0.08 | — | — |
Q1 2023 | Mar 9, 2023 | — | $-0.08 | — | — |
Q1 2023 | Mar 7, 2023 | — | $-0.15 | — | — |
Q1 2023 | Feb 27, 2023 | — | $-3.34 | — | — |
Q2 2022 | May 13, 2022 | — | $-0.12 | — | — |
Q1 2022 | Feb 14, 2022 | — | $-0.13 | — | — |
Q4 2021 | Nov 15, 2021 | — | $-0.20 | — | — |
Q3 2021 | Sep 24, 2021 | — | $-0.35 | — | — |
Q2 2021 | May 17, 2021 | — | $-0.09 | — | — |
Q1 2021 | Feb 16, 2021 | — | $-0.06 | — | — |
Q4 2020 | Nov 12, 2020 | — | $-0.05 | — | — |
Latest News
Frequently Asked Questions about ENOB
What is ENOB's current stock price?
What is the analyst price target for ENOB?
What sector is Enochian Biosciences, Inc. in?
What is ENOB's market cap?
Does ENOB pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ENOB for comparison